Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA)
CUSIP: 687604108
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 50,314,906
- Total 13F shares
- 24,559,501
- Share change
- +24,537,934
- Total reported value
- $604,174,991
- Price per share
- $24.51
- Number of holders
- 41
- Value change
- +$603,646,384
- Number of buys
- 40
Quarterly Holders Quick Answers
What is CUSIP 687604108?
CUSIP 687604108 identifies ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2024
Recent filing periods for CUSIP 687604108:
Top shareholders of ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Funicular Funds, LP |
3/4/5
|
Other*, 10%+ Owner |
—
mixed-class rows
|
9,179,356
mixed-class rows
|
$22,903,390 | — | 15 Dec 2022 | |
| Funicular Fund, LP |
3/4/5
|
Other* |
—
mixed-class rows
|
2,594,952
mixed-class rows
|
$6,451,130 | — | 23 May 2022 | |
| JANUS HENDERSON GROUP PLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,117,213
|
$6,302,520 | — | 16 Aug 2024 | |
| Christopher David Ozeroff |
3/4/5
|
S.V.P., General Counsel |
—
mixed-class rows
|
78,470
mixed-class rows
|
$127,425 | — | 14 Dec 2021 | |
| Robert E. Conway |
3/4/5
|
Director, Chairman of the Board |
—
mixed-class rows
|
56,000
mixed-class rows
|
$125,000 | — | 30 Jan 2024 | |
| Thomas A. Keuer |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
40,730
|
$101,825 | — | 08 Dec 2022 | |
| C. Jeffrey Dekker |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
40,000
|
$100,000 | — | 08 Dec 2022 | |
| Michael R. Bristow |
3/4/5
|
Pres. & Chief Executive Offic, Director |
—
mixed-class rows
|
99,808
mixed-class rows
|
$12,021 | — | 14 Dec 2021 | |
| Daniel J. Mitchell |
3/4/5
|
Director |
—
mixed-class rows
|
6,611
mixed-class rows
|
$1,528 | — | 30 Jan 2024 | |
| Anders D. Hove |
3/4/5
|
Director |
—
class O/S missing
|
6,000
|
— | — | 30 Jan 2024 | |
| James P. Flynn |
3/4/5
|
Director |
—
class O/S missing
|
6,000
|
— | — | 30 Jan 2024 | |
| Linda Grais |
3/4/5
|
Director |
—
class O/S missing
|
6,000
|
— | — | 30 Jan 2024 | |
| Raymond L. Woosley |
3/4/5
|
Director |
—
class O/S missing
|
6,000
|
— | — | 30 Jan 2024 |
Institutional Holders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) as of Q3 2024
As of 30 Sep 2024,
Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,559,501 shares.
The largest 10 holders included
FMR LLC, Fairmount Funds Management LLC, VR Adviser, LLC, RTW INVESTMENTS, LP, COMMODORE CAPITAL LP, PERCEPTIVE ADVISORS LLC, Deep Track Capital, LP, Avidity Partners Management LP, FRANKLIN RESOURCES INC, and Paradigm Biocapital Advisors LP.
This page lists
42
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q4 2025 Across Filers
Q4 2025 holders
143
Q3 2024 holders
41
Holder diff
-102
| Investor | Q4 2025 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.